Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity

被引:231
作者
Solomon, Daniel H. [1 ]
Kremer, Joel [2 ]
Curtis, Jeffrey R. [3 ]
Hochberg, Marc C. [4 ,5 ]
Reed, George [6 ]
Tsao, Peter
Farkouh, Michael E. [7 ]
Setoguchi, Soko
Greenberg, Jeffrey D. [8 ]
机构
[1] Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA
[2] Albany Med Coll, Div Rheumatol, Albany, NY 12208 USA
[3] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA
[4] Univ Maryland, Sch Med, Dept Med, Div Clin Immunol & Rheumatol, Baltimore, MD 21201 USA
[5] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Div Gerontol, Baltimore, MD 21201 USA
[6] Univ Massachusetts, Amherst, MA 01003 USA
[7] Mt Sinai Heart, Clin Trials Unit, New York, NY USA
[8] NYU, Sch Med, Div Rheumatol, NYU Hosp Joint Dis, New York, NY USA
关键词
CORONARY-HEART-DISEASE; UNITED-STATES ADULTS; INFLAMMATORY POLYARTHRITIS; MYOCARDIAL-INFARCTION; MORTALITY; PREVALENCE; ATHEROSCLEROSIS; PREDICTION; VALIDITY; EVENTS;
D O I
10.1136/ard.2009.122226
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cardiovascular (CV) disease has a major impact on patients with rheumatoid arthritis (RA), however, the relative contributions of traditional CV risk factors and markers of RA severity are unclear. The authors examined the relative importance of traditional CV risk factors and RA markers in predicting CV events. Methods A prospective longitudinal cohort study was conducted in the setting of the CORRONA registry in the USA. Baseline data from subjects with RA enrolled in the CORRONA registry were examined to determine predictors of CV outcomes, including myocardial infarction, stroke or transient ischemic attack. Possible predictors were of two types: traditional CV risk factors and markers of RA severity. The discriminatory value of these variables was assessed by calculating the area under the receiver operating characteristic curve (c-statistic) in logistic regression. The authors then assessed the incidence rate for CV events among subjects with an increasing number of traditional CV risk factors and/or RA severity markers. Results The cohort consisted of 10 156 patients with RA followed for a median of 22 months. The authors observed 76 primary CV events during follow-up for a composite event rate of 3.98 (95% CI 3.08 to 4.88) per 1000 patient-years. The c-statistic improved from 0.57 for models with only CV risk factors to 0.67 for models with CV risk factors plus age and gender. The c-statistic improved further to 0.71 when markers of RA severity were also added. The incidence rate for CV events was 0 (95% CI 0 to 5.98) for persons without any CV risk factors or markers of RA severity, while in the group with two or more CV risk factors and three or more markers of RA severity the incidence was 7.47 (95% CI 4.21 to 10.73) per 1000 person-years. Conclusions Traditional CV risk factors and markers of RA severity both contribute to models predicting CV events. Increasing numbers of both types of factors are associated with greater risk.
引用
收藏
页码:1920 / 1925
页数:6
相关论文
共 40 条
[1]  
Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100
[2]   Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score [J].
Aletaha, D ;
Nell, VP ;
Stamm, T ;
Uffmann, M ;
Pflugbeil, S ;
Machold, K ;
Smolen, JS .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) :R796-R806
[3]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[4]  
Choi HK, 2005, J RHEUMATOL, V32, P2311
[5]   Methotrexate and mortality in patients with rheumatoid arthritis:: a prospective study [J].
Choi, HK ;
Hernán, MA ;
Seeger, JD ;
Robins, JM ;
Wolfe, F .
LANCET, 2002, 359 (9313) :1173-1177
[6]   Increased coronary-artery atherosclerosis in rheumatoid arthritis - Relationship to disease duration and cardiovascular risk factors [J].
Chung, CP ;
Oeser, A ;
Raggi, P ;
Gebretsadik, T ;
Shintani, AK ;
Sokka, T ;
Pincus, T ;
Avalos, I ;
Stein, CM .
ARTHRITIS AND RHEUMATISM, 2005, 52 (10) :3045-3053
[7]   Use and misuse of the receiver operating characteristic curve in risk prediction [J].
Cook, Nancy R. .
CIRCULATION, 2007, 115 (07) :928-935
[8]   Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis [J].
del Rincón, I ;
Freeman, GL ;
Haas, RW ;
O'Leary, DH ;
Escalante, A .
ARTHRITIS AND RHEUMATISM, 2005, 52 (11) :3413-3423
[9]   Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects [J].
del Rincón, I ;
Williams, K ;
Stern, MP ;
Freeman, GL ;
O'Leary, DH ;
Escalante, A .
ARTHRITIS AND RHEUMATISM, 2003, 48 (07) :1833-1840
[10]  
Dessein PH, 2007, J RHEUMATOL, V34, P943